A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
Top Cited Papers
Open Access
- 13 April 2019
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 236 (9) , 2653-2666
Abstract
Background 5-methoxy-N,N-dimethyltryptamine (hereinafter referred to as 5-MeO-DMT) is a psychedelic substance found in the secretion from the parotoid glands of the Bufo alvarius toad. Inhalation of vapor from toad secretion containing 5-MeO-DMT has become popular in naturalistic settings as a treatment of mental health problems or as a means for spiritual exploration. However, knowledge of the effects of 5-MeO-DMT in humans is limited. Aims The first objective of this study was to assess sub-acute and long-term effects of inhaling vapor from dried toad secretion containing 5-MeO-DMT on affect and cognition. The second objective was to assess whether any changes were associated with the psychedelic experience. Methods Assessments at baseline, within 24 h and 4 weeks following intake, were made in 42 individuals who inhaled vapor from dried toad secretion at several European locations. Results Relative to baseline, ratings of satisfaction with life and convergent thinking significantly increased right after intake and were maintained at follow-up 4 weeks later. Ratings of mindfulness also increased over time and reached statistical significance at 4 weeks. Ratings of depression, anxiety, and stress decreased after the session, and reached significance at 4 weeks. Participants that experienced high levels of ego dissolution or oceanic boundlessness during the session displayed higher ratings of satisfaction with life and lower ratings of depression and stress. Conclusion A single inhalation of vapor from dried toad secretion containing 5-MeO-DMT produces sub-acute and long-term changes in affect and cognition in volunteers. These results warrant exploratory research into therapeutic applications of 5-MeO-DMT.Keywords
Funding Information
- Czech Ministery of Interior Affairs (VI20172020056)
- Czech Ministery of Education, Youth and Sports (LO1611)
- Charles University Prague (PROGRES Q35)
This publication has 45 references indexed in Scilit:
- Synaptic Dysfunction in Depression: Potential Therapeutic TargetsScience, 2012
- Psychedelics and the Human ReceptoromePLOS ONE, 2010
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in ratsPsychopharmacology, 2006
- The short‐form version of the Depression Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a large non‐clinical sampleBritish Journal of Clinical Psychology, 2005
- Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-TryptamineJournal of Psychoactive Drugs, 2001
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in HumansPharmacopsychiatry, 1998
- Bufo alvarius: a potent hallucinogen of animal originJournal of Ethnopharmacology, 1994
- Pharmacology and toxicology of toad venomJournal of Pharmaceutical Sciences, 1967
- 5-Methoxy- and 5-Hydroxyindoles in the skin of Bufo alvariusBiochemical Pharmacology, 1967